185 related articles for article (PubMed ID: 19247981)
21. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
22. Investigational drug tracking: phases I-III and NDA submissions--Part II.
Grant KL
Hosp Pharm; 1994 Oct; 29(10):900, 902-4, 906-11 passim. PubMed ID: 10137850
[TBL] [Abstract][Full Text] [Related]
23. [Contact and dialogue between drug companies and the global regulatory authorities throughout research and development phase].
Kock M; Thomsen MK
Ugeskr Laeger; 2003 Apr; 165(16):1649-52. PubMed ID: 12756820
[TBL] [Abstract][Full Text] [Related]
24. Economics of new oncology drug development.
DiMasi JA; Grabowski HG
J Clin Oncol; 2007 Jan; 25(2):209-16. PubMed ID: 17210942
[TBL] [Abstract][Full Text] [Related]
25. Obstacles and opportunities in new drug development.
Kaitin KI
Clin Pharmacol Ther; 2008 Feb; 83(2):210-2. PubMed ID: 18202685
[No Abstract] [Full Text] [Related]
26. Investigational drug tracking: Phases I-III and NDA submissions--Part I.
Grant KL
Hosp Pharm; 1994 Sep; 29(9):830-6, 839-44, 847-52 passim. PubMed ID: 10137064
[TBL] [Abstract][Full Text] [Related]
27. Current regulatory perspectives on genotoxicity testing for botanical drug product development in the U.S.A.
Wu KM; Dou J; Ghantous H; Chen S; Bigger A; Birnkrant D
Regul Toxicol Pharmacol; 2010 Feb; 56(1):1-3. PubMed ID: 19782117
[TBL] [Abstract][Full Text] [Related]
28. The economics of pediatric formulation development for off-patent drugs.
Milne CP; Bruss JB
Clin Ther; 2008 Nov; 30(11):2133-45. PubMed ID: 19108801
[TBL] [Abstract][Full Text] [Related]
29. Charging for investigational drugs under an investigational new drug application. Final rule.
Food and Drug Administration, HHS
Fed Regist; 2009 Aug; 74(155):40871-900. PubMed ID: 19691172
[TBL] [Abstract][Full Text] [Related]
30. Alternative strategies in drug development: clinical pharmacological aspects.
Kuhlmann J
Int J Clin Pharmacol Ther; 1999 Dec; 37(12):575-83. PubMed ID: 10599949
[TBL] [Abstract][Full Text] [Related]
31. [Clinical researchers and pharmaceutical industry. Dangerous liaisons].
Roos JC
Ned Tijdschr Geneeskd; 1999 Aug; 143(32):1668-71. PubMed ID: 10494304
[TBL] [Abstract][Full Text] [Related]
32. Drug research: from the idea to the product.
Kuhlmann J
Int J Clin Pharmacol Ther; 1997 Dec; 35(12):541-52. PubMed ID: 9455711
[TBL] [Abstract][Full Text] [Related]
33. Two ideas to increase innovation and reduce pharmaceutical costs and prices.
Jayadev A; Stiglitz J
Health Aff (Millwood); 2009; 28(1):w165-8. PubMed ID: 19088104
[TBL] [Abstract][Full Text] [Related]
34. The strategic interaction between firms and formulary committees: effects on the prices of new drugs.
García-Alonso MD; García-Mariñoso B
J Health Econ; 2008 Mar; 27(2):377-404. PubMed ID: 18276026
[TBL] [Abstract][Full Text] [Related]
35. Barriers to clinical trials vary according to the type of trial and the institution.
Govindarajan R; Young JW; Harless CL; Hutchins LF
J Clin Oncol; 2007 Apr; 25(12):1633-4; author reply 1634. PubMed ID: 17443010
[No Abstract] [Full Text] [Related]
36. Scale and scope in drug development: unpacking the advantages of size in pharmaceutical research.
Cockburn IM; Henderson RM
J Health Econ; 2001 Nov; 20(6):1033-57. PubMed ID: 11758047
[TBL] [Abstract][Full Text] [Related]
37. Phase 0 clinical trials in oncology: a paradigm shift for early drug development?
Takimoto CH
Cancer Chemother Pharmacol; 2009 Mar; 63(4):703-9. PubMed ID: 18615251
[TBL] [Abstract][Full Text] [Related]
38. Current good manufacturing practice and investigational new drugs intended for use in clinical trials. Final rule.
Food and Drug Administration, HHS
Fed Regist; 2008 Jul; 73(136):40453-63. PubMed ID: 18850678
[TBL] [Abstract][Full Text] [Related]
39. Should insurance be responsible for the cost of care while a patient is enrolled in a clinical trial?
Weiss PA
Clin J Oncol Nurs; 2008 Feb; 12(1):153-4. PubMed ID: 18258585
[No Abstract] [Full Text] [Related]
40. [Clinical research and pharmaceutical industry. A relationship with advantages and disadvantages].
ten Cate JW; Büller HR
Ned Tijdschr Geneeskd; 1999 Jul; 143(30):1572-6. PubMed ID: 10443284
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
